TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/03/2026
Back to search
Official data from USPTO
TRANSDERMAL CONTINUOUS O2 THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
TRANSDERMAL CONTINUOUS O2 THERAPY
ST13
US500000085290022Class
10
Filing
85290022
Registration
4110440
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
06/05/2026
Trademark type
Word
Nice classes
10
Filing date
04/08/2011
Registration date
03/06/2012
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/25/2022
Last transaction
06/05/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Supplemental Register
First use anywhere
2009-01-00
First use in commerce
2009-01-00
Drawing code
4
Owner type
16
Owner location
Fort Lauderdale, FL, US
Examiner
FLOWERS, JAY K
Law office
M30
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Neogenix LLC
Representatives
Gregory M. Stone Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 10
medical instrumentan electronic medical appliance for wound healing
Publications
History of USPTO decisions and trademark events.
30 publications found
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/03/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/03/2026
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
08/25/2022
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
08/25/2022
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
08/25/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/25/2022
E89R
TEAS SECTION 8 & 9 RECEIVED
03/07/2022
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
03/06/2021
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
04/10/2017
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
04/10/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/10/2017
ES8R
TEAS SECTION 8 RECEIVED
03/17/2017
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/06/2017
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
03/06/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
01/31/2012
ALIE
ASSIGNED TO LIE
01/30/2012
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
01/12/2012
XAEC
EXAMINER'S AMENDMENT ENTERED
01/12/2012
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/12/2012
GNEA
EXAMINERS AMENDMENT E-MAILED
01/12/2012
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/12/2012
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/12/2012
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/12/2011
GNRT
NON-FINAL ACTION E-MAILED
07/12/2011
CNRT
NON-FINAL ACTION WRITTEN
07/12/2011
DOCK
ASSIGNED TO EXAMINER
07/12/2011
MPMK
NOTICE OF PSEUDO MARK MAILED
04/13/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/12/2011
NWAP
NEW APPLICATION ENTERED
04/12/2011
Continuous trademark protection
Get notified about every new filing that threatens TRANSDERMAL CONTINUOUS O2 THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.